Literature DB >> 29902699

Abuse of fentanyl: An emerging problem to face.

Katarzyna Kuczyńska1, Piotr Grzonkowski1, Łukasz Kacprzak1, Jolanta B Zawilska2.   

Abstract

Fentanyl is a potent synthetic opioid used as a narcotic analgesic supplement in general and regional anesthesia as well as in management of persistent, severe chronic pain. Alarming epidemiological and forensic medicine reports, accumulated mainly during the last two decades, point to a growing increase in illicit use of fentanyl, mainly in North America and Europe. Toxicological data indicates that fentanyl use is inextricably linked with polydrug use. There are two main sources of fentanyl on the "recreational" drug market. First, the most common, combines illicitly manufactured fentanyl from clandestine sources. The drug is often mixed up with heroin ("fake heroin") to increase its potency at a little cost, or included in cocaine products. It can also be mixed into and sold as oxycodone-, hydrocodone- or alprazolam-containing tablets. The other way to gain fentanyl is through the diversion of fentanyl-containing medicines, especially transdermal patches (FTPs). Fentanyl extracted from FTP can be administered intravenously, insufflated or inhaled after volatilization. The drug can also be delivered by oral or transmucosal application of the whole patch, or by rectal insertion. The most common overdose symptoms are coma, lethargy, respiratory depression and arrest. Although naloxone, an opioid receptor antagonist, is the standard drug for fentanyl overdose rescue, attempts to revive patients with naloxone could be unsuccessful, due to the rapid onset of fentanyl's action. As the fentanyl problem is constantly growing, there is an urgent need for new, effective harm-reduction strategies and technologies, as well as overdose maintenance.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Abuse; Fentanyl; Naloxone; Overdose; Synthetic opioids; Transdermal fentanyl patches

Mesh:

Substances:

Year:  2018        PMID: 29902699     DOI: 10.1016/j.forsciint.2018.05.042

Source DB:  PubMed          Journal:  Forensic Sci Int        ISSN: 0379-0738            Impact factor:   2.395


  30 in total

1.  Fentanyl Preference among People Who Inject Drugs in West Virginia.

Authors:  Alyona Mazhnaya; Allison O'Rourke; Rebecca Hamilton White; Ju Nyeong Park; Michael E Kilkenny; Susan G Sherman; Sean T Allen
Journal:  Subst Use Misuse       Date:  2020-05-22       Impact factor: 2.164

2.  Toward the Interpretation of Positive Testing for Fentanyl and Its Analogs in Real Hair Samples: Preliminary Considerations.

Authors:  A Salomone; R Bigiarini; J J Palamar; C McKnight; L Vinsick; E Amante; D Di Corcia; M Vincenti
Journal:  J Anal Toxicol       Date:  2020-05-18       Impact factor: 3.367

Review 3.  Interpol review of controlled substances 2016-2019.

Authors:  Nicole S Jones; Jeffrey H Comparin
Journal:  Forensic Sci Int Synerg       Date:  2020-05-24

Review 4.  Risk Factors Associated with the Occurrence of Neonatal Opioid Withdrawal Syndrome: A Review.

Authors:  Erin Kelty; David B Preen
Journal:  CNS Drugs       Date:  2019-11       Impact factor: 5.749

5.  An Easy to Implement Approach for Laboratories to Visualize Particle Spread During the Handling and Analysis of Drug Evidence.

Authors:  Edward Sisco; Matthew E Staymates; Amber Burns
Journal:  Forensic Chem       Date:  2020

6.  A Stepwise Approach for Preventing Suicide by Lethal Poisoning.

Authors:  Jasmine E Carpenter; Tiffany Lee; Elizabeth Greene; Eileen Holovac
Journal:  Fed Pract       Date:  2021-02

Review 7.  Translational value of non-human primates in opioid research.

Authors:  Huiping Ding; Mei-Chuan Ko
Journal:  Exp Neurol       Date:  2021-01-14       Impact factor: 5.330

8.  Demand for fentanyl becomes inelastic following extended access to fentanyl vapor self-administration.

Authors:  Sam A McConnell; Adam J Brandner; Brandon A Blank; David N Kearns; George F Koob; Leandro F Vendruscolo; Brendan J Tunstall
Journal:  Neuropharmacology       Date:  2020-10-20       Impact factor: 5.250

9.  Fentanyl conjugate vaccine by injected or mucosal delivery with dmLT or LTA1 adjuvants implicates IgA in protection from drug challenge.

Authors:  Addison E Stone; Sarah E Scheuermann; Colin N Haile; Gregory D Cuny; Marcela Lopez Velasquez; Joshua P Linhuber; Anantha L Duddupudi; Jennifer R Vigliaturo; Marco Pravetoni; Therese A Kosten; Thomas R Kosten; Elizabeth B Norton
Journal:  NPJ Vaccines       Date:  2021-05-13       Impact factor: 7.344

10.  Cannabis Significantly Reduces the Use of Prescription Opioids and Improves Quality of Life in Authorized Patients: Results of a Large Prospective Study.

Authors:  Philippe Lucas; Susan Boyd; M-J Milloy; Zach Walsh
Journal:  Pain Med       Date:  2021-03-18       Impact factor: 3.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.